Kezar Life Sciences is a clinical-stage biotechnology company developing novel small molecule therapeutics for immune-mediated diseases. Its lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor in development for autoimmune hepatitis (AIH) and previously studied in lupus nephritis and SLE. Following inability to align with the FDA on a registrational trial, the company announced strategic alternatives and a wind-down of operations in October 2025, while continuing to pursue FDA guidance for zetomipzomib in AIH.
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001628280-26-021737 | EDGAR | 71K words |
| 2025-03-25 | 2024-12-31 | 0001645666-25-000010 | EDGAR | 74K words |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031494 | EDGAR | 76K words |
| 2023-03-14 | 2022-12-31 | 0000950170-23-007871 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004085 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012525 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010498 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001564590-19-009369 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001628280-25-051623 | EDGAR | 51K words |
| 2025-08-13 | 2025-06-30 | 0001645666-25-000037 | EDGAR | 50K words |
| 2025-05-13 | 2025-03-31 | 0001645666-25-000027 | EDGAR | 48K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125457 | EDGAR | 55K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096213 | EDGAR | 53K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056918 | EDGAR | 51K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062950 | EDGAR | 56K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041332 | EDGAR | 51K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021257 | EDGAR | 49K words |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024486 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016897 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009686 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001628280-26-023703 | EDGAR | 3K words |
| 2026-03-30 | 0001193125-26-130486 | EDGAR | 2K words |
| 2026-03-12 | 0001628280-26-017046 | EDGAR | 17K words |
| 2025-11-12 | 0001628280-25-051592 | EDGAR | 1K words |
| 2025-11-07 | 0001628280-25-050671 | EDGAR | 1K words |
| 2025-10-22 | 0001628280-25-045871 | EDGAR | 1K words |
| 2025-10-16 | 0001628280-25-045215 | EDGAR | 1K words |
| 2025-08-13 | 0001645666-25-000036 | EDGAR | 2K words |
| 2025-06-23 | 0001645666-25-000029 | EDGAR | 1K words |
| 2025-05-13 | 0001645666-25-000026 | EDGAR | 2K words |
145 total filings indexed. 115 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001645666 |
| Ticker | KZR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.kezarlifesciences.com |
| Listed | 2018-06-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KZR (~200 tokens, structured JSON with cryptographic provenance)